γ-氨基丁酸治疗对哮喘患儿血浆P物质和降钙素基因相关肽含量的影响

Effect of gamma-aminobutyric acid treatment on plasma substance P and calcitonin gene-related peptide levels in children with asthma

摘要:

目的：探讨γ-氨基丁酸（GABA）治疗前后哮喘患儿血浆P物质（SP）和降钙素基因相关肽(CGRP)含量的变化。方法：75例哮喘患儿随机分为GABA治疗组（36例）和对照组（39例），两组患儿均给予哮喘常规治疗。治疗组在常规治疗的基础上给予GABA口服 (每日25~30 mg/kg）。采用酶联免疫吸附法（ELISA）测定患儿治疗前、缓解后血浆SP、CGRP的含量。结果：两组患儿治疗前血浆SP、CGRP含量差异无统计学意义（P＞0.05）；哮喘缓解后治疗组血浆SP、CGRP含量分别为57±15 pg/mL、23±10 pg/mL，显著低于对照组（分别为127±12 pg/mL、 42±8 pg/mL），差异有统计学意义（P<0.01）。两组哮喘缓解后血浆SP、CGRP含量均较治疗前明显下降，差异有统计学意义（P<0.01）。哮喘患儿血浆SP与CGRP含量呈显著正相关（r=0.792，P<0.01）。结论：GABA可抑制小儿哮喘急性发作期血浆SP、CGRP的释放。

Abstract:

OBJECTIVE: To study the changes in plasma substance P (SP) and calcitonin gene-related peptide (CGRP) levels in children with acute asthma before and after gamma-aminobutyricacid (GABA) treatment. METHODS: Seventy-five children with asthma were randomly assigned to GABA treatment (n=36) and control groups (n=39). Both groups were given conventional treatment for asthma. Besides the conventional treatment, the treatment group was administered with oral GABA (25-30 mg/kg?d). Plasma content of SP and CGRP was measured using ELISA before treatment and after remission. RESULTS: There were no significant differences in plasma content of SP and CGRP between the GABA treatment and control groups (P＞0.05) before treatment. Plasma content of SP and CGRP in the GABA treatment group was significantly lower than the control group (SP: 57±15 pg/mL vs 127±12 pg/mL; CGRP: 23±10 pg/mL vs 42±8 pg/mL) after remission (P<0.01). Plasma content of SP and CGRP after remission was significantly lower than before treatment (P<0.01) in both groups. There was a significantly positive correlation between plasma SP and CGRP content in asthmatic children (r=0.792, P<0.01). CONCLUSIONS: GABA can significantly decrease plasma levels of SP and CGRP in children suffering from acute asthma.